Results 31 to 40 of about 17,566 (194)

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology

مجلة كلية الطب, 2015
Background: Primary myelofibrosis is characterized by clonal expansion of hematopoietic stem cell with a non-reactive clonal proliferation of fibroblasts and bone marrow fibrosis, which occurs at an extramedullary hematopoiesis.
Alaa F. Alwan
doaj   +1 more source

Analysis of MicroRNA -155-5p Expression in Patients with Primary Myelofibrosis.

مجلة كلية الطب
Background: Primary myelofibrosis is a chronic myeloproliferative neoplasm characterized by abnormal megakaryocyte proliferation and fibrosis that destroys healthy bone marrow.
Sarah I. Khaleel, Jaffar N. AlAlsaidissa   +1 more
doaj   +1 more source

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

Haematologica, 2011
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein, Donna M. Williams, Christine O’Keefe, Ophelia Rogers, Roxann G. Ingersoll, Jerry L. Spivak, Amit Verma, Jarek P. Maciejewski, Michael A. McDevitt, Alison R. Moliterno   +9 more
doaj   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, EarlyView.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

The regulation of stem cell fate and its application in neural regeneration

Interdisciplinary Medicine, EarlyView.
Regulating stem cell fate is crucial for neural regeneration. This review summarizes key physical, biological, and chemical strategies and their applications in repairing nerve injuries, providing new insights for regenerative medicine. Abstract Regulating the fate of stem cells (SCs) is a key technical problem in the field of regenerative medicine and
Yuexin He, Xingyu Chen, Minghong He, Zhe Li   +3 more
wiley   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Hematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Raquel Tognon, Natalia de Souza Nunes, Belinda Pinto Simões, Lorena Lôbo de Figueiredo-Pontes, Luiz Fernando Bazzo Catto, Fabíola Traina, Elizabeth Xisto Souto, Fabiana Albani Zambuzi, Fabiani Gai Frantz, Fabíola Attié de Castro   +11 more
doaj   +1 more source

TP53 mutations and Polymorphisms in Primary Myelofibrosis, [PDF]

Blood, 2011
Abstract Abstract 3840 Background: Patients with myeloproliferative neoplasms (MPN) harbor a multitude of somatic mutations involving JAK2, MPL, LNK, CBL, TET2, ASXL1, IDH1, IDH2, EZH2, DNMT3A, IKZF1 and TP53.
Sania, Raza, David, Viswanatha, Lori, Frederick, Terra, Lasho, Christy, Finke, Ryan, Knudson, Rhett, Ketterling, Animesh, Pardanani, Ayalew, Tefferi   +8 more
openaire   +2 more sources

Unveiling the roles of extracellular vesicles in hematologic malignancies: Pathogenesis, diagnostic tools, and clinical translation

Interdisciplinary Medicine, EarlyView.
Extracellular vesicles play pivotal roles in both healthy hematopoiesis and hematologic malignancies. They not only regulate hematopoietic stem cell fitness but also drive cancer progression and drug resistance. Their clinical potential spans from serving as non‐invasive biomarkers to acting as innovative therapeutic platforms and drug delivery ...
Fengyu Chen, Zhiyuan Wu, Feng Zhang, Yuan Meng, Hongyan Liao, Tony Y. Hu   +5 more
wiley   +1 more source

Triple immunostaining demonstrates the possible existence of segregated-nucleus-containing atypical monocytes in human primary myelofibrosis bone marrow: a case report

Journal of Medical Case Reports
Background Segregated-nucleus-containing atypical monocytes have recently been identified in mice. Segregated-nucleus-containing atypical monocytes are thought to originate from the bone marrow and induce fibrosis in the drug-injured lung.
Shunsuke Homma, Toshie Ogasawara, Michie Suga, Yoshiyasu Nakamura, Katsuya Takenaka, Shoko Marshall, Kiyotaka Kawauchi, Naoki Mori, Hajime Kuroda, Naoya Nakamura, Yohei Miyagi, Atsuko Masunaga   +11 more
doaj   +1 more source